NEW YORK and NASSAU, The Bahamas, May 1 /PRNewswire-FirstCall/ -- Fincor (Pink Sheets: FINC) through a share split with Prospero Group (Pink Sheets: PRPG), a leading company in the field of water technologies, enlarges its portfolio with the new ACTRx Malaria and Dengue fever treatment. Fincor also acquired the WETTECH and Advanced Cavitation Technologies.
Fincor, acquired a majority of ACTRx International Inc., which combines several natural drugs to fight Malaria and Dengue fever and looks to become a premier global supplier of Malaria and Dengue cures, preventatives, maintenance and information products and services.
According to the World Health Organization, over 3 billion people live in areas at risk of malaria transmission, and annually over one million deaths are attributable to it -- 90% of which are to children under the age of five. However, malaria is a preventable and treatable disease, and the United Nations has called for elimination of all malaria deaths by the end of 2015, a goal which President Obama committed the United States to supporting on April 24th, 2009. The pharmaceutical package available through ACTRx will be a strong leader in the global fight against these unnecessary deaths from malaria. Additionally, it will assist in protecting and treating the 2.5 billion people at risk from dengue fever, and the 5 million dengue infections that occur each year. Prospero Group's intention is to research, review and objectively resolve the issues that keep these diseases active in our global society.
Fincor also acquired WETTECH marketed as Prospero Water Technologies and the Advanced Cavitation Technology.
About Fincor Inc.: Fincor Inc. is a technology and pharmaceutical company. It has recently acquired ACTRx International Inc. which produces Malaria and Dengue fever drugs in order to become the premier global supplier of Malaria and Deng
|SOURCE Fincor Inc.|
Copyright©2009 PR Newswire.
All rights reserved